Risk of liability for damages arising from defects or malfunctions in our medical-related products
First written in FY2020. 2 of 3 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 11 of 57 companies on the "Worse" side.
125 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「If an unforeseeable defect or malfunction occurs in one of the company’s products, the company may face claims for damages from medical institutions and other parties, resulting in substantial damages payments and litigation costs.」
The risk of damages and litigation costs arising from defects or malfunctions in the company’s medical products remains. - FY2022RestatedAnnual report
「If an unforeseeable defect or malfunction occurs in one of the company’s products, the company may face claims for damages from medical institutions and other parties, resulting in substantial damages payments and litigation costs.」
The risk of damages and litigation costs arising from defects or malfunctions in the company’s medical products remains. - FY2020First statedAnnual report
「The Group’s manufacturing subsidiaries make every effort to implement quality control and other measures to minimise risk. However, if an unforeseeable defect or malfunction occurs in one of the company’s products, the company may face claims for damages from medical institutions and other parties, resulting in substantial damages payments and litigation costs.」
The company has newly disclosed the possibility of damages claims and litigation costs arising from unexpected defects or malfunctions in its products, while implementing quality control.